Announcing our Annual Report 2020: hot off the press
An Annual Report with a difference, for a year like none other
Journal of Hepatology ranking soars, remaining the leader among specialist hepatology journals
ClarivateTM Analytics released the 2021 update of its Journal Citation Reports©, including the much anticipated 2020 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2020 impact factor of 25.083, up from the 2019…
Discover the making-of the International Liver Congress 2021
We would like to thank every single participant who took part in this year's ILC, held 23–26 June 2021. The event brought together almost 6,500 delegates from over 100 countries, who took part in 155 sessions, listened to 566 presentations…
Treatment advances for Non-Alcoholic Fatty Liver Disease (NAFLD) announced at ILC 2021
For Immediate Release Media Release Treatment advances for Non-Alcoholic Fatty Liver Disease (NAFLD) announced at ILC 2021 New data released on trials involving RNAi therapeutics, antivirals and structurally engineered fatty acids to treat NAFLD Friday 25 June 2021 (Geneva, Switzerland)--…
A highlight of ILC 2021: a triumvirate of Nobel Laureates
In EASL Studio, we were honoured to keep company with the three 2020 Nobel Laureates, awarded the 2020 Nobel Prize for Physiology and Medicine for their discovery of the hepatitis C virus. They reflected on many thought-provoking topics: the exponential…
Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021
For Immediate Release Media Release Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021 Thursday 24 June 2021 (Geneva, Switzerland)-- Leading hepatology researchers announced important new developments in hepatitis research at the International…
ILC 2021 opens with focus on impact of COVID-19 on global liver disease
For Immediate Release Media Release ILC 2021 opens with focus on impact of COVID-19 on global liver disease New data demonstrates that chronic liver disease increased the odds of COVID-19 death by 80% and Pfizer-BioNTech COVID-19 vaccine confers low immunity on people with advanced…
EASL supports International NASH Day 2021: NASH Around the World
8 June 2021 EASL is delighted to be officially endorsing International NASH Day 2021: NASH Around the World, conducted by the Global Liver Institute (GLI), this Thursday, 10 June. Non-alcoholic steatohepatitis (NASH), the advanced form of non-alcoholic fatty liver disease (NAFLD), is a life-threatening disease…
Honouring the European Week Against Cancer 2021, ending on World No Tobacco Day
31 May 2021 This European Week Against Cancer, EASL has contributed in many ways to tackling liver cancer: signing a joint-society statement, contributing to a White Paper, and taking part in several webinars.